A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)-Reference-Cited by-同舟云学术

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Published:2010-12-20 Issue:5 Volume:70 Page:747-754
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Annals of the Rheumatic Diseases

Author:

Quartier P.,Allantaz F.,Cimaz R.,Pillet P.,Messiaen C.,Bardin C.,Bossuyt X.,Boutten A.,Bienvenu J.,Duquesne A.,Richer O.,Chaussabel D.,Mogenet A.,Banchereau J.,Treluyer J.-M.,Landais P.,Pascual V.

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Cited by 466 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-1 receptor antagonism reveals a yin-yang relationship between NFκB and interferon signaling in chronic lymphocytic leukemia;Proceedings of the National Academy of Sciences;2024-08-09

2. Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials;Rheumatology;2024-05-22

3. Self-inflicted very-low-velocity penetrating head injury: A CARE-compliant case report;Medicine;2024-05-03

4. Comparative efficacy and safety of different drugs in patients with systemic juvenile idiopathic arthritis: A systematic review and network meta-analysis;Medicine;2024-05-03

5. Efficacy and safety of an early response‐based tapering regimen of tocilizumab in children with systemic juvenile idiopathic arthritis;International Journal of Rheumatic Diseases;2024-05